Mineralys Therapeutics Common Target Price

Key Indicators . Target Price . Stocks . USA . 
Stock . Mineralys Therapeutics Common
MLYS Stock   29.35  -0.77  -2.56%   
Mineralys Therapeutics' Target Price page includes the metric definition, calculation formula, and current value. The reported reading aligns with the most recent filing period.
=

46.13

The Target Price figure for Mineralys Therapeutics is sourced from the most recent financial disclosure. The dataset is maintained in line with ongoing disclosure updates.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Profitability
Analysis
Details
Earnings
Projections
Details

Target Price Peer Comparison

Peer comparison on Target Price is one of the most widely used methods for evaluating Mineralys Therapeutics relative to competitors. Comparing Mineralys Therapeutics' Target Price against peers surfaces securities trading below their model-implied intrinsic value estimate in the group.
Mineralys Therapeutics is currently under evaluation in target price relative to competitors.

Important Fundamentals

Return On Equity TTM-0.37
Return On Asset TTM-0.25
Current Valuation1.79 B
Shares Outstanding82.45 M
Shares Owned By Insiders0.72 %
Shares Owned By Institutions99.28 %
Number Of Shares Shorted8.78 M
Price To Book TTM3.78 X
EBITDA TTM-170.6 M
Net Income TTM-154.65 M
Total Debt TTM15.11 M
Book Value Per Share TTM7.93 X
Cash Flow From Operations TTM-142.42 M
Short Ratio TTM6.15 X
Earnings Per Share-2.29 X
Target Price46.13
Number Of Employees76
Trailing Beta0.48
Market Capitalization TTM2.48 B
Total Asset TTM661.81 M
Retained Earnings TTM-457.17 M
Working Capital TTM646.27 M
Net Asset661.81 M

Financial Metrics, Fundamentals & Methodology

Mineralys Therapeutics's operating framework helps explain margin behavior, earnings persistence, and funding capacity. The company is currently operating at a loss. Overall market capitalization tier is mid-cap. For the latest reporting period, Mineralys Therapeutics reports EPS loss of 2.29.

Mineralys Therapeutics Common metrics draw on periodic company reporting and market reference feeds, standardized for cross-period comparison. Reported income, balance-sheet, and cash-flow fields adhere to GAAP or IFRS presentation rules.

Editorial review and methodology oversight provided by: Ellen Johnson, Member of Macroaxis Editorial Board


 
Tools
Analysis
Directory
Company
2026 Macroaxis LLC Made with in San Francisco
Privacy Terms Widgets Feedback
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and conditions page.